Survodutide

Timing

A general projection of what people report noticing over time, based on the known mechanism and reported use patterns. It is not a guarantee and individual experience varies considerably.

1. 1

   1–2 Weeks

   Appetite reduction is typically the first noticeable change, consistent with its GLP-1 receptor activity, similar in onset to other GLP-1-class compounds.

2. 2

   3–4 Weeks

   A sense of increased energy expenditure alongside continued appetite suppression is reported by some trial participants during dose escalation.

3. 3

   5–7 Weeks

   Early, gradual weight changes may begin to be noticed.

4. 4

   8–10 Weeks

   Continued weight and appetite changes are typical through this period, per available trial data.

5. 5

   11–15 Weeks

   Sustained weight loss trends are generally reported through this window in trial participants.

6. 6

   16–20 Weeks

   This stage is commonly associated with clearly visible body composition changes in available trial data.

7. 7

   21–24 Weeks

   Many trial participants are approaching a maintenance phase by this point, per published Phase 2 data.

⚠️ Research context only. This is not medical advice and results are not guaranteed.